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Iron deficiency anemia is a common complication in
end-stage renal disease (ESRD) and impairs the therapeutic
efficacy of recombinant erythropoietin. Oral or parental
iron supplements usually are effective in treating iron
deficiency anemia. Some patients, however, respond poorly
to iron supplements and are diagnosed as having iron-
refractory iron deficiency anemia. The condition exacerbates
ESRD but its underlying mechanism was unclear. Hepcidin
is a central player in iron homeostasis. It downregulates
the iron exporter ferroportin, thereby inhibiting iron
absorption, release and recycling. In ESRD, plasma hepcidin
levels are elevated, which contributes to iron deficiency in
patients. Matriptase-2, a liver transmembrane serine
protease, has been found to have a major role in controlling
hepcidin gene expression. In mice, defects in the Tmprss6
gene encoding matriptase-2 result in high hepcidin
expression and cause severe microcytic anemia. Similarly,
mutations in the human TMPRSS6 gene have been
identified in patients with iron-refractory iron deficiency.
Thus, matriptase-2 is critical for iron homeostasis and
may have an important role in ESRD.
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ANEMIA IN END-STAGE RENAL DISEASE
Anemia is a common complication in patients with end-stage
renal disease (ESRD), as a result of progressive loss of
erythropoietin (EPO) production in the kidney. Recombi-
nant human EPO is used to treat anemia in ESRD patients. In
many ESRD patients, however, high doses of recombinant
human EPO fail to boost red blood cell counts to an adequate
level.1 The poor response to EPO therapy, or EPO resistance,
is a major problem, which increases the morbidity and
mortality in ESRD patients.2
Iron deficiency is a major cause of EPO resistance. Up to
B40% of patients with EPO resistance had low levels of
serum ferritin or transferrin saturation.3 As iron is an
essential element in hemoglobin, when iron is in short
supply, hemoglobin production is impaired. In ESRD
patients, EPO resistance often reflects an underlying defect
in iron homeostasis. In fact, a hemodialysis patient may lose
up to 3mg/day of iron as a result of blood loss (up to
B20ml) during each treatment.4 This amount of iron loss
exceeds B1 to 2mg of daily dietary iron intake, which
inevitably leads to iron store depletion and iron deficiency
anemia. In comparison, peritoneal dialysis patients, who
suffer much less blood loss related to the dialysis procedure,
are less likely to have iron deficiency than hemodialysis
patients.5
There are many other causes that may contribute to EPO
resistance, including inflammation, dialysis procedures,
hyperparathyroidism, uremia, aluminum toxicity, auto anti-
bodies, and vitamin deficiency. These topics are covered by
comprehensive reviews1,6–8 and will not be discussed here.
Most patients with iron deficiency anemia can be treated
by oral or parental iron supplements. In ESRD patients,
intravenous iron supplements significantly improve the
therapeutic efficacy of recombinant human EPO.9 However,
some patients with iron deficiency anemia respond poorly to
iron therapy. The condition is known as iron-refractory iron
deficiency anemia (IRIDA), which is characterized by a
hypochromic and microcytic anemia with a low mean
corpuscular erythrocyte volume, a low serum iron level,
low transferrin saturation, an increased ferritin level, and
a normal level of serum soluble transferrin receptor (see
review10 for laboratory diagnosis). The disease represents a
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medical challenge but, for many years, its cause was unclear.
Most recently, genetic studies have provided new insights
into its underlying mechanisms.
IRON ABSORPTION AND BALANCE
Plasma and cellular iron levels are tightly regulated by
mechanisms that control iron absorption, storage, recycling
and release.11 To absorb iron, the insoluble ferric iron (Fe3þ )
from vegetables and grains needs to be converted into the
ferrous form (Fe2þ ) by a brush border ferric reductase in the
duodenum and upper jejunum. The ferrous iron then is
transferred across the enterocyte membrane by divalent metal
transporter-1. The heme iron from red meat has a better
bioavailability than that of the inorganic iron, and its
absorption appears to be mediated by a different molecular
mechanism.
In blood, iron is carried by transferrin to various tissues to
be taken up by cells in a transferrin receptor-mediated
endocytotic process.11 Once inside the cell, iron is released
from transferrin in the acidic endosome and stored in the
form of ferritin. A significant portion, up to B75%, of
plasma iron is taken up by bone marrow to make
hemoglobin in red blood precursors. Several other cell types
including enterocytes, hepatocytes, and reticuloendothelial
macrophages also serve as major iron storage sites.
When plasma iron levels are low, iron release is increased
from enterocytes, hepatocytes, and macrophages to meet the
physiological demand. Conversely, when plasma iron levels
are high, iron will remain stored in these cells. The body loses
iron when cells are shed from the gastrointestinal tract or
blood is lost, for example, during hemodialysis. Curiously,
our body lacks a way to excrete iron from the kidney, which
differs from how plasma sodium levels are adjusted. As a
result, regulated iron release from cellular storage sites
becomes a major mechanism to control plasma iron levels.
FERROPORTIN AND HEPCIDIN IN IRON HOMEOSTASIS
The release of iron from the cell is mediated by an exporter
called ferroportin,11 a transmembrane protein on the surface
of the iron-storing cells. Ferroportin exports iron from the
intracellular storage pool, thereby increasing plasma iron
levels. The exporter also is responsible for iron release from
macrophages after erythrophagocytosis.12 This macrophage-
mediated iron recycling process provides the majority of iron
supply for hemoglobin production in red blood cells.
Hepcidin is a peptide produced primarily in the liver. Its
mature form consists of 25 amino acids with a calculated
mass of 2.8 kDa. Hepcidin has a key role in iron homeostasis
by interacting with ferroportin.13 When it binds to
ferroportin, hepcidin induces phosphorylation of the iron
exporter, causing its internalization and degradation in
lysosomes (Figure 1). As a result, hepcidin lowers ferroportin
protein level on the cell surface, thereby inhibiting iron
export from intracellular pools. Thus, hepcidin controls
plasma iron level by reducing iron absorption in the gut,
lowering iron release from hepatocytes, and preventing iron
recycling by macrophages (Figure 1). Hepcidin expression
also was detected in the kidney14 but the biological
significance of this finding is not clear.
The importance of hepcidin in iron metabolism has been
shown in genetic studies. In mice, for example, disrupting the
hepcidin gene caused iron accumulation in the liver,
pancreas, and heart, increased serum iron levels, and reduced
iron content in the spleen.15 Conversely, overexpression of
hepcidin in transgenic mice resulted in decreased body iron
levels and severe microcytic anemia.16 Similar findings also
have been reported in humans. Some patients with large
hepatic adenomas had significantly high levels of hepcidin
expression and decreased serum transferrin saturation.17
The patients developed severe anemia who responded poorly
to iron therapy.
HEPCIDIN IN PATIENTS WITH RENAL DISEASE
High levels of plasma or serum hepcidin have been found in
patients with chronic renal disease.18–20 In ESRD patients
receiving hemodialysis or peritoneal dialysis, plasma hepcidin
levels appeared to be even higher.18,20,21 The mechanism
underlying high hepcidin expression in ESRD patients is not
clear but may reflect chronic inflammation in these patients.
Inflammatory cytokines are strong stimuli for hepcidin
expression (see below). Inflammatory monocytes and
macrophages also express hepcidin, which, in an autocrine
manner, reduces ferroportin expression and retains iron in
these cells.22,23 The data are consistent with the impaired iron
absorption/recycling and low hemoglobin levels in ESRD
patients. In addition to its role in iron metabolism, hepcidin
may have a direct effect on erythropoiesis. In cell culture,
hepcidin was shown to antagonize EPO-mediated erythroid
colony formation, suggesting a possibility of hepcidin in
inhibiting erythroid progenitor growth and/or survival.24
This potential function of hepcidin needs to be verified in
in vivo studies, and its significance in EPO resistance in ESRD
patients remains to be determined.
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Figure 1 |Hepcidin downregulates ferroportin expression on
the cell surface. Ferroportin (FPN) is expressed on the surface of
enterocytes, hepatocytes, and tissue macrophages. The binding of
hepcidin to FPN leads to its phosphorylation, internalization, and
degradation. Low levels of FPN expression reduce iron absorption
in the gut, lower iron release from the liver, and prevent iron
recycling by tissue macrophages.
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HEPCIDIN GENE REGULATION
The Hamp gene, encoding hepcidin, is expressed primarily in
the liver. Bone morphogenetic proteins (BMPs) are major
activators for Hamp gene expression.25,26 The binding of
BMP to its cell surface receptor activates the SMAD signaling
pathway and induces Hamp gene expression.27 Hemojuvelin,
a glycosylphosphatidylinositol-anchored membrane protein,
acts as a co-receptor for BMP to promote Hamp gene
expression. In humans and mice, mutations in the hemoju-
velin gene reduce hepcidin expression and cause iron
overload in the liver, pancreas, and heart, but reduced iron
levels in tissue macrophages.28
In addition to BMP and hemojuvelin, other molecules also
regulate hepcidin expression. For example, interleukin-6 was
reported to stimulate hepcidin expression, possibly through
the JAK/STAT3 signaling pathway.29 On the other hand,
growth differentiation factor-15 and hypoxia-inducible
transcription factors suppress hepcidin expression.29 In vitro
and in vivo studies have shown that growth differentiation
factor-15 expression was induced in response to iron
depletion and in patients with iron deficiency anemia.30 It
appears that growth differentiation factor-15-mediated
hepcidin inhibition is an important mechanism in regulating
iron homeostasis.
The induction of hepcidin expression by inflammatory
cytokines has important implications in the anemia of
chronic disease.31 Dialysis patients are known to have chronic
inflammation. High levels of interleukin-6 in dialysis patients
were associated with poor clinical outcomes.32 In these
patients, elevated levels of inflammatory cytokines such as
interleukin-6 are expected to stimulate hepcidin expression,
which will lead to reduced iron absorption in the gut and
iron retention in macrophages,33–36 thereby inhibiting
erythropoiesis. Consistently, inflammatory biomarkers were
linked to anemia and poor responses to EPO treatment in
patients.37,38
MATRIPTASE-2/TMPRSS6 IN IRON METABOLISM AND ANEMIA
Matriptase-2, also called TMPRSS6, is a type II transmem-
brane serine protease.39 It consists of a short cytoplasmic tail
at the N terminus, a transmembrane domain and an
extracellular region that includes a SEA (sea urchin sperm
protein, enteropeptidase, and agrin) domain, two CUB
(complement factor C1s/C1r, urchin embryonic growth
factor, and BMP) domains, three low-density lipoprotein
receptor repeats, and a trypsin-like protease domain at the C
terminus (Figure 2). Matriptase-2 is highly expressed in the
liver. Low levels of matriptase-2 mRNA were detected in the
kidney, uterus, brain, adrenal gland, and testis.
Recent studies revealed a critical role of matriptase-2 in
iron metabolism. In a chemically induced mutant mouse
strain, mask characterized by extensive loss of body hair and
microcytic anemia, the Tmprss6 gene encoding matriptase-2
was found to be disrupted by a premature stop codon.40
In these mice, dietary iron absorption was significantly
reduced as a result of markedly increased hepcidin levels.
Similar findings of alopecia and severe IDA were reported in
Tmprss6/ mice created by gene knockout.41 Tmprss6/
mice also had reduced ferroportin expression and iron
accumulation in enterocytes. These studies show an
important role of matriptase-2 in suppressing hepcidin
expression.
Mutations in the human TMPRSS6 gene have been found
in patients with IRIDA. Several groups have identified
nonsense, missense, frameshift, and splice junction mutations
in the TMPRSS6 gene in patients with familial or sporadic
IRIDA42–45 (Figure 2). In all families analyzed to date, the
disease appeared to be inherited in an autosomal recessive
manner. In these patients, high levels of hepcidin were
present in their urine samples, consistent with the idea that
TMPRSS6 gene mutations led to higher hepcidin expression,
thereby preventing iron absorption and causing IRIDA. These
new findings prompted further studies to understand how
matriptase-2 inhibits hepcidin expression.
Matriptase-2 is a trypsin-like enzyme.39 A possible
explanation for matriptase-2-mediated hepcidin inhibition
is that the enzyme degrades hepcidin proteolytically. This
hypothesis, however, was unlikely because in mice disrupting
the Tmprss6 gene increased hepcidin mRNA levels, suggesting
that matriptase-2 acted at the transcriptional level.40,41
Consistently, overexpression of matriptase-2 inhibited the
Hamp promoter activity.40 Most recently, matriptase-2 was
shown to degrade hemojuvelin in cell membrane.46 As
hemojuvelin is a co-receptor for BMP to promote hepcidin
expression, matriptase-2 seems to inhibit hepcidin expression
by degrading hemojuvelin (Figure 3a). In patients and
mutant mice, therefore, matriptase-2 deficiency results in
elevated hemojuvelin and, subsequently, hepcidin levels. This
leads to impaired iron absorption/recycling and in turn
causes IRIDA (Figure 3b). Together, the latest studies have
provided the first insight into the biological function of
matriptase-2 and its role in iron homeostasis.
PERSPECTIVE
Iron is essential for life. Regulatory mechanisms have been
evolved, allowing the body to obtain sufficient amounts of
iron from the environment and yet preventing its possible
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Figure 2 |Matriptase-2 domain structure and mutants
identified in patients with iron-refractory iron deficiency
anemia (IRIDA). Matriptase-2 consists of an N-terminal
transmembrane domain (TM), one SEA (sea urchin sperm protein,
enteropeptidase, and agrin) domain, two CUB (complement factor
C1s/C1r, urchin embryonic growth factor, and bone
morphogenetic proteins) domains, three low-density lipoprotein
(LDL) receptor repeats (LDLR), and a C-terminal trypsin-like
protease domain. Relative positions of nonsense ("), missense
(E), splicing junction (#), and frameshift (!) mutations
identified in patients with IRIDA are indicated.
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toxic effect of overload. Hepcidin has been identified as a
central regulator in iron homeostasis. Now a critical role of
matriptase-2 has been discovered in regulating hepcidin
expression and in IRIDA. Membrane serine proteases are
known to be involved in maintaining homeostasis. The
transmembrane protease corin in the heart, for example,
activates atrial natriuretic peptide, a cardiac hormone that
regulates sodium homeostasis and blood pressure.47–49
Matriptase-2 shares structural similarities with corin but
instead functions in the liver to regulate iron homeostasis. It
will be important to determine if additional structurally
related membrane proteases are involved in regulating other
metal elements that are of metabolic importance.
The finding of the matriptase-2 function in regulating
hepcidin expression encourages more research to understand
its role in renal disease, in which abnormal iron metabolism
is common. How are matriptase-2 expression and activity
regulated in ESRD patients? Is it possible that a decreased
matriptase-2 activity contributes to elevated plasma hepcidin
levels and exacerbates anemia in these patients? Can we take
pharmacological approaches to enhance matriptase-2 expres-
sion and/or activity to improve iron absorption and prevent
anemia? As iron deficiency and anemia are important
complications in renal disease, studies to answer these and
many other questions about matriptase-2 and hepcidin may
lead to better diagnosis and treatment for ESRD patients.
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